Program
pegcetacoplan
Also written as “Pegcetacoplan”, “APL-2” and “PEGCETACOPLAN (APL-2)”.
Its studies are mostly in Geographic Atrophy · Hemoglobinuria, Paroxysmal · Glomerulonephritis, Membranoproliferative · Anemia, Hemolytic, Autoimmune · Macular Degeneration, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 244 open or running | phase 3since Apr 10, 2018 | Oct 8, 2014 | Jun 25, 2027phase 2 · NCT07215390 |
| Swedish Orphan Biovitrum | 42 open or running | phase 4since Mar 26, 2026 | Oct 15, 2021 | Jan 17, 2031phase 3 · NCT07898774 |
| AbbVie | 11 open or running | phase 2since Aug 12, 2025 | Aug 12, 2025 | Oct 2029phase 2 · NCT07160179 |
| Hoffmann-La Roche | 10 open or running | phase 1since Apr 29, 2025 | Apr 29, 2025 | none ahead |
Also a collaborator on its studies: iqvia-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Oct 8, 2014.
- Feb 23, 2021Phase 3 study in Geographic Atrophy Secondary to Age-related Macular DegenerationBiogen · NCT04770545 · 792 enrolled · United States, Argentina, Australia and more
- Mar 8, 2021Phase 2 study in Hemoglobinuria, ParoxysmalBiogen · NCT04901936 · 12 planned · United States, Czechia, France and more
- Sep 23, 2021Phase 3 study in Glomerulonephritis, MembranoproliferativeBiogen · NCT05067127 · 124 enrolled · United States, Argentina, Australia and more
- Oct 15, 2021Swedish Orphan Biovitrum's first study: phase 3 study in Anemia, Hemolytic, AutoimmuneNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT05096403 · 24 enrolled · United States, Austria, Belgium and more
- Oct 21, 2021Phase 2 study in Transplant-Associated Thrombotic MicroangiopathySwedish Orphan Biovitrum · NCT05148299 · 12 enrolled · United States, France, Greece and more
- Mar 30, 2023Phase 3 study in Glomerulonephritis, MembranoproliferativeBiogen · NCT05809531 · 100 enrolled · United States, Argentina, Australia and more
- Apr 29, 2025Hoffmann-La Roche's first study: phase 1 study in Geographic AtrophyNew to Hoffmann-La RocheHoffmann-La Roche · NCT06961370 · 27 enrolled · United States
- Jun 6, 2025Phase 3 study in Delayed Graft FunctionBiogen · NCT07020832 · Brazil
- Jun 30, 2025Phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationBiogen · NCT07215390 · 240 planned · United States
- Aug 12, 2025AbbVie's first study: phase 2 study in Geographic AtrophyNew to AbbVieAbbVie · NCT07160179 · 66 planned · United States
- Sep 15, 2025Phase 3 study in FSGSBiogen · NCT07213960 · 270 planned · United States
- Oct 6, 2025Phase 3 study in Geographic AtrophyBiogen · NCT07214740 · 44 enrolled · United States
- Mar 26, 2026Phase 4 study in GlomerulonephritisSwedish Orphan Biovitrum · NCT07746895 · 150 planned · Australia, Austria, Belgium and more
- Oct 21, 2026Phase 3 study in C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Swedish Orphan Biovitrum · NCT07898774 · 30 planned · Brazil, Canada, Finland and more
Ahead
- Jun 25, 2027Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationBiogen · NCT07215390
- Jul 2027Primary completion: phase 3 study in Glomerulonephritis, MembranoproliferativeBiogen · NCT05809531
- Dec 2028Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalBiogen · NCT04901936
- Oct 2029Primary completion: phase 3 study in FSGSBiogen · NCT07213960
TargetBeta
“A pegylated peptide inhibitor of human complement components C3 and C3b, ”NCIt, by rule
“Complement C3 inhibitor”ChEMBL 37, by rule
Other programs on C3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SSS55rule | 3SBio | phase 1 | 1 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07898774C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) · Brazil, Canada, Finland and more | 3 | Recruiting | Swedish Orphan Biovitrum | Jan 17, 2031 | 30 |
| NCT07746895Glomerulonephritis · Australia, Austria, Belgium and more | 4 | Recruiting | Swedish Orphan Biovitrum | Dec 31, 2031 | 150 |
| NCT07214740Geographic Atrophy · United States | 3 | Completed | Biogen | Dec 12, 2025 | 44 |
| NCT07213960FSGS · United States | 3 | Recruiting | Biogen | Oct 2029 | 270 |
| NCT07160179Geographic Atrophy · United States | 2 | Recruiting | AbbVie | Oct 2029 | 66 |
| NCT07215390Geographic Atrophy Secondary to Age-related Macular Degeneration · United States | 2 | Recruiting | Biogen | Jun 25, 2027 | 240 |
| NCT07020832Delayed Graft Function · Brazil | 3 | Withdrawn | Biogen | Jun 2029 | 0 |
| NCT06961370Geographic Atrophy · United States | 1 | Terminated | Hoffmann-La Roche | Feb 3, 2026 | 27 |
| NCT05809531Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Biogen | Jul 2027 | 100 |
| NCT05148299Transplant-Associated Thrombotic Microangiopathy · United States, France, Greece and more | 2 | Completed | Swedish Orphan Biovitrum | Dec 8, 2024 | 12 |
| NCT05096403Anemia, Hemolytic, Autoimmune · United States, Austria, Belgium and more | 3 | Completed | Swedish Orphan Biovitrum | May 27, 2024 | 24 |
| NCT05067127Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more | 3 | Completed | Biogen | Jun 26, 2024 | 124 |
| NCT04901936Hemoglobinuria, Paroxysmal · United States, Czechia, France and more | 2 | Recruiting | Biogen | Dec 2028 | 12 |
| NCT04770545Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Argentina, Australia and more | 3 | Completed | Biogen | Sep 5, 2025 | 792 |
| NCT04572854Glomerulonephritis, Membranoproliferative · United States, Argentina, Australia and more | 2 | Completed | Biogen | Feb 27, 2023 | 13 |
| NCT04579666Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more | 2 | Terminated | Biogen | Mar 31, 2023 | 249 |
| NCT04085601Hemoglobinuria, Paroxysmal · Colombia, Hong Kong, Malaysia and more | 3 | Completed | Biogen | Jun 23, 2021 | 53 |
| NCT03777332Geographic Atrophy · United States | 1 | Completed | Biogen | Apr 1, 2021 | 19 |
| NCT03593200Hemoglobinuria, Paroxysmal · Bulgaria, Serbia | 2 | Completed | Biogen | Oct 22, 2019 | 4 |
| NCT03531255PNH · United States, Australia, Belgium and more | 3 | Completed | Biogen | Sep 4, 2025 | 137 |
| NCT03525613Geographic Atrophy · United States, Australia, Brazil and more | 3 | Completed | Biogen | Jun 28, 2021 | 637 |
| NCT03525600Geographic Atrophy · United States, Argentina, Australia and more | 3 | Completed | Biogen | Jun 21, 2021 | 621 |
| NCT03500549Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more | 3 | Completed | Biogen | Nov 14, 2019 | 80 |
| NCT03465709Neovascular Age-related Macular Degeneration · United States | 2 | Terminated | Biogen | Apr 5, 2019 | 17 |
| NCT03453619Glomerulonephritis, IGA · United States | 2 | Completed | Biogen | Apr 16, 2020 | 21 |
| NCT03226678Anemia, Hemolytic, Autoimmune · United States | 2 | Completed | Biogen | Sep 12, 2022 | 24 |
| NCT02588833Hemoglobinuria, Paroxysmal · Hong Kong, Malaysia, New Zealand and more | 1 | Completed | Biogen | Aug 26, 2019 | 23 |
| NCT02503332Geographic Atrophy · United States, Australia, New Zealand | 2 | Completed | Biogen | Jul 14, 2017 | 246 |
| NCT02461771Neovascular Age-Related Macular Degeneration · United States, Australia | 1 | Completed | Biogen | Mar 8, 2016 | 13 |
| NCT02264639Hemoglobinuria, Paroxysmal · United States | 1 | Completed | Biogen | Oct 22, 2018 | 9 |
How it is read
Names in the registry
- “Pegcetacoplan”, 17 entries
- “APL-2”, 7 entries
- “PEGCETACOPLAN (APL-2)”, 2 entries
- “APL-3007, pegcetacoplan (APL-2)”, 2 entries
- “Syfovre™”, 1 entry
Conditions, from the studies’ own filings
- Geographic Atrophy, 9 studies
- Hemoglobinuria, Paroxysmal, 6 studies
- Glomerulonephritis, Membranoproliferative, 4 studies
- Anemia, Hemolytic, Autoimmune, 2 studies
- Macular Degeneration, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.